Onco-Innovations Limited is pleased to announce that it has entered into a letter of intent (the "LOI") with Inka Health Corp. ("Inka Health"), an arms-length party holding a state-of-the-art proprietary artificial intelligence platform ("Inka Platform"). Through this potential acquisition, the Company aims to leverage Inka Health's cutting-edge SynoGraph™ technology, a transformative AI-powered tool designed to accelerate precision oncology breakthroughs while de-risking drug development processes. The LOI sets out the terms upon which, subject to due diligence, Onco would acquire all of the outstanding share capital of Inka Health ("Inka Shares"), incorporating the Inka Platform into its drug discovery and development pipeline.

Under the terms of the LOI, the Company, subject to completion of satisfactory due diligence and other customary conditions, would acquire all of the Inka Shares in exchange for such number of common shares of the Company ("Consideration Shares") as are equal to $3,000,000, based on  closing price. All of the Consideration Shares will be subject to resale restrictions whereby 10% will be tradeable four months from the closing date of the transaction ("Closing Date"), 15% of the remaining Consideration Shares will be tradeable within six months from the Closing Date, and a further 15% of the remaining amount will be tradeable every six months thereafter. These resale restrictions will be in addition to any resale restrictions required pursuant to applicable securities laws.

Inka Health is a Canadian-based software company pioneering the use of advanced AI-driven analytics and real-world multimodal data to revolutionize clinical research and drug development. Its proprietary SynoGraph™ platform integrates genomic, proteomic, and multimodal data, offering insights into disease mechanisms, potentially enabling highly personalized treatment strategies. The platform emulates precision-medicine clinical trials, which carries the potential to significantly reduce the time and cost associated with late-stage drug discovery and clinical research. With access to vast genomics datasets through partnerships and the expertise of Inka Health's Scientific Advisor, Dr. Steven Jones, Head of Bioinformatics and Co-Director of the Genome Sciences Centre in Vancouver, and a Distinguished Scientist at the BC Cancer Research Institute, Inka Health is uniquely positioned to drive advancements in precision oncology.¹

Among its notable collaborations, Inka Health has partnered with one of the world's largest pharmaceutical companies, AstraZeneca Canada, as well as global data holders Quantify Research. These partnerships demonstrate Inka Health's commitment to fostering collaboration with industry leaders and its ability to deliver transformative solutions in precision medicine.

"The reason we went public is so we could get access to opportunities like this. We are incredibly excited about Inka Health as a potential acquisition, as it has the AI tools which could help improve cancer detection and precision treatment, as well as already having established contracts with some of the largest pharmaceutical companies in the world," said Thomas O'Shaughnessy, CEO of the Company.

The global artificial intelligence (AI) in healthcare market is experiencing unprecedented growth and is projected to soar to USD 613.81 billion by 2034, with a remarkable compound annual growth rate (CAGR) of 36.83%. North America continues to dominate the market, generating over 45% of total revenue in 2023, driven by its advanced digital infrastructure and strong healthcare, IT, and telecommunications sectors.²